Silence Therapeutics (SLN) Receivables (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Receivables for 7 consecutive years, with $28000.0 as the latest value for Q3 2025.
- Quarterly Receivables changed N/A to $28000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $28000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $972000.0 for FY2024, 235.17% up from the prior year.
- Receivables hit $28000.0 in Q3 2025 for Silence Therapeutics, down from $85000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.1 million in Q4 2022 to a low of $28000.0 in Q3 2025.
- Historically, Receivables has averaged $418343.4 across 5 years, with a median of $282982.6 in 2023.
- Biggest five-year swings in Receivables: plummeted 98.85% in 2021 and later soared 243.48% in 2024.
- Year by year, Receivables stood at $446191.5 in 2021, then skyrocketed by 140.53% to $1.1 million in 2022, then plummeted by 73.63% to $282982.6 in 2023, then skyrocketed by 243.48% to $972000.0 in 2024, then crashed by 97.12% to $28000.0 in 2025.
- Business Quant data shows Receivables for SLN at $28000.0 in Q3 2025, $85000.0 in Q2 2025, and $41000.0 in Q1 2025.